Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Debt (2021 - 2023)

Standard Biotools (LAB) has disclosed Non-Current Debt for 5 consecutive years, with $3.4 million as the latest value for Q4 2023.

  • Quarterly Non-Current Debt fell 58.34% to $3.4 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2023, down 58.34% year-over-year, with the annual reading at $3.4 million for FY2023, 58.34% down from the prior year.
  • Non-Current Debt for Q4 2023 was $3.4 million at Standard Biotools, down from $4.6 million in the prior quarter.
  • The five-year high for Non-Current Debt was $10.2 million in Q2 2022, with the low at $3.4 million in Q4 2023.
  • Average Non-Current Debt over 3 years is $7.9 million, with a median of $8.8 million recorded in 2022.
  • The sharpest move saw Non-Current Debt dropped 6.14% in 2022, then tumbled 58.34% in 2023.
  • Over 3 years, Non-Current Debt stood at $10.0 million in 2021, then decreased by 18.46% to $8.2 million in 2022, then plummeted by 58.34% to $3.4 million in 2023.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $3.4 million, $4.6 million, and $5.8 million for Q4 2023, Q3 2023, and Q2 2023 respectively.